Fight CRC Clinical Trial Finder
| NCT ID | Title | Phase | Date Added | Location | Prior IO Allowed | CRC-directed | Status | Drugs | Tags |
|---|---|---|---|---|---|---|---|---|---|
| NCT ID NCT03400332 |
TitleA Study of BMS-986253 in Combination With Nivolumab or Nivolumab Plus Ipilimumab in Advanced Cancers | Phase
Phase 1, Phase 2
|
Date Added 2018-01-17 |
Location
Arkansas, United States
California, United States Colorado, United States Georgia, United States Maryland, United States Massachusetts, United States Michigan, United States Nebraska, United States Nevada, United States New Jersey, United States New York, United States Oklahoma, United States Oregon, United States Pennsylvania, United States South Carolina, United States Texas, United States Utah, United States Virginia, United States Australia Belgium Canada France Germany Italy Poland Spain Sweden Switzerland United Kingdom |
Prior IO Allowed No |
CRC-directed No |
Status
Active, not recruiting
|
Drugs
BMS-986253, Ipilimumab, Nivolumab |
Tags
MSI-H/ MMRd, MSS/ MMRp
|
| NCT ID NCT03217747 |
TitleAvelumab, Utomilumab, Anti-OX40 Antibody PF-04518600, and Radiation Therapy in Treating Patients With Advanced Malignancies | Phase
Phase 1, Phase 2
|
Date Added 2017-07-14 |
Location
Texas, United States
|
Prior IO Allowed No |
CRC-directed No |
Status
Active, not recruiting
|
Drugs
Anti-OX40 Antibody PF-04518600, Avelumab, Utomilumab, Bavencio |
Tags
MSS/ MMRp
|
| NCT ID NCT05141721 |
TitleA Study of a Personalized Neoantigen Vaccine in Combination With Immune Checkpoint Blockade for Patients With Metastatic Colorectal Cancer | Phase
Phase 2
|
Date Added 2021-12-02 |
Location
Arizona, United States
Arkansas, United States California, United States Colorado, United States Connecticut, United States Florida, United States Illinois, United States Indiana, United States Kansas, United States Kentucky, United States Maryland, United States Michigan, United States Nevada, United States New Jersey, United States New York, United States Ohio, United States Oregon, United States Pennsylvania, United States South Carolina, United States Tennessee, United States Texas, United States Utah, United States Virginia, United States Wisconsin, United States |
Prior IO Allowed No |
CRC-directed Yes |
Status
Active, not recruiting
|
Drugs
Atezolizumab, Bevacizumab, Fluoropyrimidine, GRT-C901, GRT-R902, Ipilimumab, oxaliplatin |
Tags
MSS/ MMRp
|
| NCT ID NCT03530397 |
TitleA Study to Evaluate MEDI5752 in Subjects With Advanced Solid Tumors | Phase
Phase 1
|
Date Added 2018-05-21 |
Location
Michigan, United States
New York, United States North Carolina, United States Rhode Island, United States Tennessee, United States Virginia, United States Australia France Italy Korea, Republic of Netherlands Portugal Spain Taiwan |
Prior IO Allowed Yes |
CRC-directed No |
Status
Active, not recruiting
|
Drugs
Carboplatin, MEDI5752, Pembrolizumab, Pemetrexed, Alimta, Imfinzi, Keytruda, Paraplatin |
Tags
MSI-H/ MMRd, MSS/ MMRp
|
| NCT ID NCT03783403 |
TitleA Study of CC-95251, a Monoclonal Antibody Directed Against SIRPα, in Participants With Advanced Solid and Hematologic Cancers | Phase
Phase 1
|
Date Added 2018-12-21 |
Location
Alabama, United States
Arizona, United States California, United States Colorado, United States Missouri, United States New York, United States North Carolina, United States Oklahoma, United States Oregon, United States Pennsylvania, United States Tennessee, United States Texas, United States Australia Canada France Italy Korea, Republic of Spain United Kingdom |
Prior IO Allowed Yes |
CRC-directed No |
Status
Active, not recruiting
|
Drugs
CC-95251, cetuximab, Rituximab |
Tags
MSS/ MMRp
|
| NCT ID NCT01061515 |
TitleBiweekly Intraperitoneal Oxaliplatin With Systemic Capecitabine and Bevacizumab for Patients With Peritoneal Carcinomatosis From Appendiceal or Colorectal Cancer | Phase
Phase 1
|
Date Added 2010-02-03 |
Location
Missouri, United States
|
Prior IO Allowed Yes |
CRC-directed Yes |
Status
Active, not recruiting
|
Drugs
Bevacizumab, capecitabine, Intraperitoneal Oxaliplatin, Avastin, Eloxatin, Xeloda |
Tags
MSS/ MMRp
|
| NCT ID NCT03981146 |
TitleA Phase II Trial Assessing Nivolumab in Class II Expressing Microsatellite Stable Colorectal Cancer | Phase
Phase 2
|
Date Added 2019-06-10 |
Location
United Kingdom
|
Prior IO Allowed No |
CRC-directed Yes |
Status
Active, not recruiting
|
Drugs
Nivolumab, Opdivo |
Tags
MSS/ MMRp
|
| NCT ID NCT04973163 |
TitleA Study to Test Different Doses of BI 1823911 Alone and Combined With Other Medicines in People With Different Types of Advanced Cancer With KRAS Mutation | Phase
Phase 1
|
Date Added 2021-07-22 |
Location
Texas, United States
Belgium Spain United Kingdom |
Prior IO Allowed No |
CRC-directed No |
Status
Active, not recruiting
|
Drugs
BI 1701963, BI 1823911, Midazolam |
Tags
MSS/ MMRp
|
| NCT ID NCT05205330 |
TitleA Phase Ib/IIa Study of CR6086 in Combination With Balstilimab in pMMR-MSS Metastatic Colorectal Cancer Patients | Phase
Phase 1, Phase 2
|
Date Added 2022-01-25 |
Location
Italy
|
Prior IO Allowed No |
CRC-directed Yes |
Status
Active, not recruiting
|
Drugs
AGEN2034, Balstilimab, CR6086 |
Tags
MSS/ MMRp
|
| NCT ID NCT03313778 |
TitleSafety, Tolerability, and Immunogenicity of mRNA-4157 Alone in Participants With Resected Solid Tumors and in Combination With Pembrolizumab in Participants With Unresectable Solid Tumors | Phase
Phase 1
|
Date Added 2017-10-18 |
Location
District of Columbia, United States
Florida, United States Massachusetts, United States New York, United States Ohio, United States Pennsylvania, United States Australia Japan United Kingdom |
Prior IO Allowed No |
CRC-directed No |
Status
Active, not recruiting
|
Drugs
mRNA-4157, Pembrolizumab, Keytruda |
Tags
MSS/ MMRp
|
